Opthea Limited

Ceryvyn Therapeutics Limited is a clinical-stage biopharmaceutical company that researches and develops therapeutic products targeting vascular endothelial growth factors (VEGF) C, D and R3. It operates in Australia and the United States. Its pipeline includes Sozinibercept, which is in phase 3 for wet age-related macular degeneration (Wet AMD) and in phase 2 for diabetic macular edema (DME). The company was formerly known as Opthea Limited and changed its name to Ceryvyn Therapeutics Limited in July 2026. It was incorporated in 1984 and is headquartered in Melbourne, Australia.